MiNK Therapeutics, Inc. Common Stock
INKTMiNK Therapeutics, Inc. (INKT) is a biotechnology company focused on developing innovative immunotherapies and personalized treatments for cancer. The company leverages its proprietary technologies to enhance immune system responses, aiming to improve outcomes for patients with various types of malignancies.
Company News
GT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runwa...
MiNK Therapeutics announced Phase II trial results for agenT-797 combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer. The study achieved a 77% disease control rate with long-term survival beyond 20 months in a subset of patients. An induction treatment strategy showed significant improvements in progression-free ...
MiNK Therapeutics announced that Phase II trial data from Memorial Sloan Kettering Cancer Center evaluating agenT-797 (an allogeneic iNKT cell therapy) combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer will be presented at AACR 2026. The study represents one of the first clinical evaluations of iNKT cell therap...
MiNK Therapeutics presented translational data at Keystone Symposia demonstrating significant depletion of iNKT cells in lung tissue from advanced IPF patients, supporting the mechanistic rationale for iNKT cell replenishment as a potential therapeutic approach. The findings expand MiNK's iNKT platform into chronic fibrotic lung disease, addressi...
MiNK Therapeutics presented clinical results showing promising immune cell therapy agenT-797 demonstrated durable responses and immune reactivation in patients with checkpoint-resistant solid tumors, with some patients experiencing complete remission lasting over two years.
